MASH / MASLD
What a GLP-1 receptor agonist actually does: which receptors it reaches, how it slows gastric emptying, and the satiety pathway it runs through.
Definition
Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease — the 2023 renamings of NASH and NAFLD. Liver fat with inflammation (MASH) or without (MASLD), driven by insulin resistance and obesity. SYNERGY-NASH (Loomba 2024 NEJM, tirzepatide) and ESSENCE (semaglutide phase 3) both showed substantial fibrosis improvement.
Tirzepatide trial reading list (incl. SYNERGY-NASH) →
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.
Other terms under Mechanism
- GLP-1 receptor
- GIP receptor
- Dual agonist
- Gastric emptying
- Food noise
- Triple agonist
- Amylin
- GLP-1 tachyphylaxis
- Non-peptide GLP-1 agonist
- A1C (glycated hemoglobin)
- TBWL (Total Body Weight Loss)
- C-peptide
- eGFR (estimated glomerular filtration rate)
- Visceral adipose tissue (VAT)
- AHI (apnea-hypopnea index)
- SNAC (oral semaglutide absorption enhancer)
Where the evidence lives
- Tirzepatide trial reading list (incl. SYNERGY-NASH)
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers